Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab

BACKGROUND: We recently reported a 56% objective response rate in patients with advanced Merkel cell carcinoma (MCC) receiving pembrolizumab. However, a biomarker predicting clinical response was not identified. METHODS: Pretreatment FFPE tumor specimens (n = 26) were stained for CD8, PD-L1, and PD-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Giraldo, Nicolas A., Nguyen, Peter, Engle, Elizabeth L., Kaunitz, Genevieve J., Cottrell, Tricia R., Berry, Sneha, Green, Benjamin, Soni, Abha, Cuda, Jonathan D., Stein, Julie E., Sunshine, Joel C., Succaria, Farah, Xu, Haiying, Ogurtsova, Aleksandra, Danilova, Ludmila, Church, Candice D., Miller, Natalie J., Fling, Steve, Lundgren, Lisa, Ramchurren, Nirasha, Yearley, Jennifer H., Lipson, Evan J., Cheever, Mac, Anders, Robert A., Nghiem, Paul T., Topalian, Suzanne L., Taube, Janis M.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6167897/
https://ncbi.nlm.nih.gov/pubmed/30285852
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0404-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars